OKYO
OKYO Pharma Limited
There isn't enough reported data to score OKYO yet.
OKYO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate OKYO's fundamentals.
OKYO PE Valuation
OKYO has no meaningful PE right now: it lost money over the past year.
OKYO Forward outlook
There aren't enough analyst estimates for OKYO to show an outlook.
OKYO Earnings Per Share
OKYO Quarterly Revenue
OKYO's revenue is shrinking: $0 last quarter.
OKYO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.4M | -$2.8M |
| Q3 2025 | -$1.5M | -$1.3M |
| Q1 2025 | -$1.6M | +$1.1M |
| Q3 2024 | -$241.5K | +$6.6M |
| Q1 2024 | -$2.7M | +$1.5M |
| Q3 2023 | -$6.8M | -$3.3M |
| Q1 2023 | -$4.2M | -$1.9M |
| Q3 2022 | -$3.5M | -$508.9K |
OKYO has burned cash in almost every quarter: −$8M over the past year, against −$17M the year before.
OKYO Net Leverage
OKYO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OKYO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 37.7 | Neutral |
OKYO's weekly RSI is 44 (neutral) and its Stochastic is 38 (neutral).
OKYO PE vs Healthcare Sector
OKYO has no meaningful PE right now: it lost money over the past year.
OKYO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.42 | 1.4% below |
| 20 week MA | $1.49 | 6% below |
| 50 week MA | $1.68 | 17% below |
| 100 week MA | $1.78 | 21% below |
| 200 week MA | $1.65 | 15% below |
OKYO is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
OKYO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $3.00 | $2.48 | -17% |
| 2023 | $2.48 | $1.77 | -29% |
| 2024 | $1.77 | $1.16 | -34% |
| 2025 | $1.16 | $1.99 | +72% |
| 2026 YTD | $1.99 | $1.40 | -30% |
OKYO has finished lower in three of the last four years. It's down 30% so far in 2026.